• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Blogs » The Carlat Psychiatry Podcast » How Effective is Esketamine [60 Sec Psych]

The Carlat Psychiatry Podcast
The Carlat Psychiatry Podcast RSS FeedRSS

Clear, engaging, and practical updates on clinical psychiatry.
Earn CME for listening to the podcast with a Podcast CME Subscription.
Listen for free here or using Apple Podcasts, Android, or Stitcher.

How Effective is Esketamine [60 Sec Psych]

May 16, 2020

It's been a year since esketamine's (Spravato) debut for treatment resistant depression, and the numbers are in: to treat and to harm. A review of Citrome L, DiBernardo A, Singh J. 144 Esketamine Nasal Spray for Management of Treatment-Resistant Depression: Number Needed to Treat, Number Needed to Harm, Likelihood to be Helped/Harmed. CNS Spectr. 2020;25(2):291‐292. [Link]


Published On: 5/16/20


Duration: 1 minute, 37 seconds

Transcript:


How effective is esketamine?


It’s been a year now since the release of esketamine – brand name Spravato – for treatment resistant depression, and the numbers are in. Leslie Citrome and colleagues pulled together 3 trials to calculate the number need to treat or harm in this industry sponsored paper from CNS Spectrums. Here’s the results, and remember that when we talk about number needed to treat, less than 10 is decent and smaller is better, but for number needed to harm we want to see big numbers…. Meaning you’d need to treat a lot of people to have a bad outcome.


The number needed to treat was 8 for response and 6 for remission. That’s in the range of most therapies for treatment resistant depression.


But how many patients are harmed by esketamine? The number needed to harm was 5 for most side effects, meaning about 1 in 5 patients will have the side effect.  Those side effects were: dissociation, vertigo, and nausea; while dizziness and altered taste were a little less common with number needed to harm of 7-9.


Esketamine did a little better when it came to long term prevention, where the number needed to treat was 4 people to prevent 1 relapse. Long-term drop out rates were also good: with only 1 in 178 patients choosing to stop maintenance esketamine.


Got feedback? Take the podcast survey.

Introducing Carlat Total Access Subscriptions

Complete access to every article you search on the website.

Shop For Total Access

Shop for Total Access
Free Psychiatry Updates
The latest unbiased psychiatric information sent to your inbox.
Specify Your Interests
Featured Book
  • AUDFB1e_CoilBound_Graphic2_transparent_sm.png

    Treating Alcohol Use Disorder: A Fact Book (2023)

    All the tools and information needed to assess and treat your patients who are struggling with...
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • canstockphoto22709844.jpg
    General Psychiatry

    Psychopharm Commandment #10: Don’t Fear these Meds

    Surprising health benefits of our riskiest meds: Lithium, quetiapine, and clozapine.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.